Clinical outcomes at 180 days after follow-up echocardiography
| Clinical outcome measures | Number of patients with event/Number of patients at risk (cumulative 180-day incidence) | HR (95% CI) | ||||
| Reduction in LAD (n=398) | No reduction in LAD (n=275) | Crude | P value | Adjusted | P value | |
| All-cause death or hospitalisation for heart failure | 52/314 (13.3%) | 60/196 (22.2%) | 0.57 (0.40 to 0.81) | 0.002 | 0.59 (0.36 to 0.97) | 0.04 |
| All-cause death | 18/344 (4.6%) | 23/230 (8.6%) | 0.48 (0.27 to 0.85) | 0.01 | 0.40 (0.18 to 0.87) | 0.02 |
| Hospitalisation for heart failure | 38/314 (9.9%) | 41/196 (15.7%) | 0.63 (0.41 to 0.97) | 0.04 | 0.77 (0.42 to 1.44) | 0.42 |
| Cardiovascular death or hospitalisation for heart failure | 46/314 (11.8%) | 51/196 (19.2%) | 0.59 (0.40 to 0.87) | 0.007 | 0.73 (0.43 to 1.24) | 0.24 |
The Cox proportional hazards regression model was constructed adjusting for 15 clinically relevant risk-adjusting variables: age ≥80 years, sex, atrial fibrillation/flutter, renal failure, anaemia, LVEF <40%, moderate/severe MR, LAD ≥40 mm, TRPG >31.4 mm Hg, change in TRPG >0 mm Hg, LVDd >55 mm, change in LVDd >0 mm, ACE-I or ARB, β-blockers and MRA.
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; LAD, left atrial diameter; LVDd, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; MRA, mineralocorticoid receptor antagonist; TRPG, tricuspid regurgitation pressure gradient.